These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 16352683)

  • 1. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.
    Teichman SL; Neale A; Lawrence B; Gagnon C; Castaigne JP; Frohman LA
    J Clin Endocrinol Metab; 2006 Mar; 91(3):799-805. PubMed ID: 16352683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog.
    Ionescu M; Frohman LA
    J Clin Endocrinol Metab; 2006 Dec; 91(12):4792-7. PubMed ID: 17018654
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse.
    Alba M; Fintini D; Sagazio A; Lawrence B; Castaigne JP; Frohman LA; Salvatori R
    Am J Physiol Endocrinol Metab; 2006 Dec; 291(6):E1290-4. PubMed ID: 16822960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Continuous subcutaneous infusions of growth hormone (GH) releasing hormone 1-44 for 14 days increase GH and insulin-like growth factor-I levels in old men.
    Corpas E; Harman SM; Piñeyro MA; Roberson R; Blackman MR
    J Clin Endocrinol Metab; 1993 Jan; 76(1):134-8. PubMed ID: 8421077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women.
    Khorram O; Laughlin GA; Yen SS
    J Clin Endocrinol Metab; 1997 May; 82(5):1472-9. PubMed ID: 9141536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog.
    Jetté L; Léger R; Thibaudeau K; Benquet C; Robitaille M; Pellerin I; Paradis V; van Wyk P; Pham K; Bridon DP
    Endocrinology; 2005 Jul; 146(7):3052-8. PubMed ID: 15817669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sustained growth hormone (GH) and insulin-like growth factor I responses to prolonged high-dose twice-daily GH-releasing hormone stimulation in middle-aged and older men.
    Veldhuis JD; Patrie JT; Frick K; Weltman JY; Weltman A
    J Clin Endocrinol Metab; 2004 Dec; 89(12):6325-30. PubMed ID: 15579798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Continuous 24-hour intravenous infusion of recombinant human growth hormone (GH)-releasing hormone-(1-44)-amide augments pulsatile, entropic, and daily rhythmic GH secretion in postmenopausal women equally in the estrogen-withdrawn and estrogen-supplemented states.
    Evans WS; Anderson SM; Hull LT; Azimi PP; Bowers CY; Veldhuis JD
    J Clin Endocrinol Metab; 2001 Feb; 86(2):700-12. PubMed ID: 11158034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men.
    Corpas E; Harman SM; Piñeyro MA; Roberson R; Blackman MR
    J Clin Endocrinol Metab; 1992 Aug; 75(2):530-5. PubMed ID: 1379256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects.
    Sackmann-Sala L; Ding J; Frohman LA; Kopchick JJ
    Growth Horm IGF Res; 2009 Dec; 19(6):471-7. PubMed ID: 19386527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuroendocrine responses to a novel growth hormone secretagogue, L-692,429, in healthy older subjects.
    Aloi JA; Gertz BJ; Hartman ML; Huhn WC; Pezzoli SS; Wittreich JM; Krupa DA; Thorner MO
    J Clin Endocrinol Metab; 1994 Oct; 79(4):943-9. PubMed ID: 7962302
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men.
    Vittone J; Blackman MR; Busby-Whitehead J; Tsiao C; Stewart KJ; Tobin J; Stevens T; Bellantoni MF; Rogers MA; Baumann G; Roth J; Harman SM; Spencer RG
    Metabolism; 1997 Jan; 46(1):89-96. PubMed ID: 9005976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of recombinant human insulin-like growth factor I administration on growth hormone (GH) secretion, both spontaneous and stimulated by GH-releasing hormone or hexarelin, a peptidyl GH secretagogue, in humans.
    Ghigo E; Gianotti L; Arvat E; Ramunni J; Valetto MR; Broglio F; Rolla M; Cavagnini F; Müller EE
    J Clin Endocrinol Metab; 1999 Jan; 84(1):285-90. PubMed ID: 9920097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of recombinant human insulin-like growth factor I administration on the growth hormone (gh) response to GH-releasing hormone in obesity.
    Maccario M; Tassone F; Gianotti L; Lanfranco F; Grottoli S; Arvat E; Muller EE; Ghigo E
    J Clin Endocrinol Metab; 2001 Jan; 86(1):167-71. PubMed ID: 11231996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Arginine counteracts the inhibitory effect of recombinant human insulin-like growth factor I on the somatotroph responsiveness to growth hormone-releasing hormone in humans.
    Gianotti L; Maccario M; Lanfranco F; Ramunni J; Di Vito L; Grottoli S; Muller EE; Ghigo E; Arvat E
    J Clin Endocrinol Metab; 2000 Oct; 85(10):3604-8. PubMed ID: 11061509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of intravenous, subcutaneous, and intranasal administration of growth hormone (GH)-releasing hormone-40 on serum GH concentrations in normal men.
    Evans WS; Vance ML; Kaiser DL; Sellers RP; Borges JL; Downs TR; Frohman LA; Rivier J; Vale W; Thorner MO
    J Clin Endocrinol Metab; 1985 Nov; 61(5):846-50. PubMed ID: 3930551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Age and secretagogue type jointly determine dynamic growth hormone responses to exogenous insulin-like growth factor-negative feedback in healthy men.
    Veldhuis JD; Weltman JY; Weltman AL; Iranmanesh A; Muller EE; Bowers CY
    J Clin Endocrinol Metab; 2004 Nov; 89(11):5542-8. PubMed ID: 15531509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of growth hormone (GH) during extended treatment of adult Japanese patients with GH deficiency (GHD).
    Chihara K; Kato Y; Kohno H; Takano K; Tanaka T; Teramoto A; Shimatsu A
    Growth Horm IGF Res; 2008 Aug; 18(4):307-17. PubMed ID: 18282776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in free rather than total insulin-like growth factor-I enhance insulin sensitivity and suppress endogenous peak growth hormone (GH) release following short-term low-dose GH administration in young healthy adults.
    Yuen K; Frystyk J; Umpleby M; Fryklund L; Dunger D
    J Clin Endocrinol Metab; 2004 Aug; 89(8):3956-64. PubMed ID: 15292333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of acute pharmacological reduction of plasma free fatty acids on growth hormone (GH) releasing hormone-induced GH secretion in obese adults with and without hypopituitarism.
    Cordido F; Fernandez T; Martinez T; Peñalva A; Peinó R; Casanueva FF; Dieguez C
    J Clin Endocrinol Metab; 1998 Dec; 83(12):4350-4. PubMed ID: 9851776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.